Robust atrophy rate measurement in Alzheimer's disease using multi-site serial MRI: Tissue-specific intensity normalization and parameter selection

Dementia Research Centre (DRC), Institute of Neurology, University College London, London, UK.
NeuroImage (Impact Factor: 6.36). 04/2010; 50(2):516-23. DOI: 10.1016/j.neuroimage.2009.12.059
Source: PubMed


We describe an improved method of measuring brain atrophy rates from serial MRI for multi-site imaging studies of Alzheimer's disease (AD). The method (referred to as KN-BSI) improves an existing brain atrophy measurement technique-the boundary shift integral (classic-BSI), by performing tissue-specific intensity normalization and parameter selection. We applied KN-BSI to measure brain atrophy rates of 200 normal and 141 AD subjects using baseline and 1-year MRI scans downloaded from the Alzheimer's Disease Neuroimaging Initiative database. Baseline and repeat images were reviewed as pairs by expert raters and given quality scores. Including all image pairs, regardless of quality score, mean KN-BSI atrophy rates were 0.09% higher (95% CI 0.03% to 0.16%, p=0.007) than classic-BSI rates in controls and 0.07% higher (-0.01% to 0.16%, p=0.07) higher in ADs. The SD of the KN-BSI rates was 22% lower (15% to 29%, p<0.001) in controls and 13% lower (6% to 20%, p=0.001) in ADs, compared to classic-BSI. Using these results, the estimated sample size (needed per treatment arm) for a hypothetical trial of a treatment for AD (80% power, 5% significance to detect a 25% reduction in atrophy rate) would be reduced from 120 to 81 (a 32% reduction, 95% CI=18% to 45%, p<0.001) when using KN-BSI instead of classic-BSI. We concluded that KN-BSI offers more robust brain atrophy measurement than classic-BSI and substantially reduces sample sizes needed in clinical trials.

Download full-text


Available from: Clifford R Jack,
1 Follower
30 Reads
  • Source
    • "All images were visually screened before preprocessing to eliminate poor quality images from the analysis. For longitudinal and/or multisite studies, the stability of image acquisition is critical but may be compromised in several ways (see Leung et al., 2010). For example, instrument-related differences between sites (e.g., scanner manufacturer, field strength) or instrument upgrades within sites may compromise image comparability (Han et al., 2006). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Trait positive affect (PA) in childhood confers both risk and resilience to psychological and behavioral difficulties in adolescence, although explanations for this association are lacking. Neurodevelopment in key areas associated with positive affect is ongoing throughout adolescence, and is likely to be related to the increased incidence of disorders of positive affect during this period of development. The aim of this study was to prospectively explore the relationship between trait indices of PA and brain development in subcortical reward regions during early to mid-adolescence in a community sample of adolescents. A total of 89 (46 male, 43 female) adolescents participated in magnetic resonance imaging assessments during both early and mid-adolescence (mean age at baseline = 12.6 years, SD = 0.45; mean follow-up period = 3.78 years, SD = 0.21) and also completed self-report measures of trait positive and negative affect (at baseline). To examine the specificity of these effects, the relation between negative affect and brain development was also examined. The degree of volume reduction in the right caudate over time was predicted by PA. Independent of time, larger hippocampal volumes were associated with higher PA, and negative affect was associated with smaller left amygdala volume. The moderating effect of negative affect on the development of the left caudate varied as a function of lifetime psychiatric history. These findings suggest that early to mid-adolescence is an important period whereby neurodevelopmental processes may underlie key phenotypes conferring both risk and resilience for emotional and behavioral difficulties later in life.
    Cognitive Affective & Behavioral Neuroscience 09/2014; DOI:10.3758/s13415-014-0319-2 · 3.29 Impact Factor
  • Source
    • ". Comparison between binary XOR of the previous BSI ( Freeborough and Fox , 1997 ; Leung et al . , 2010b , 2012 ) , fuzzy XOR of pBSI with g h 1 and g h 0 . 5 ( Ledig et al . , 2012 ) and probabilistic weighted XOR of gBSI . X axis represent the tissue displacement along the boundary , Y axis represent segmentation probabilities and red lines represent the probabilistic segmentation of the baseline and repeat images . Different boundary sh"
    [Show abstract] [Hide abstract]
    ABSTRACT: Brain atrophy measured using structural MRI has been widely used as an imaging biomarker for disease diagnosis and tracking of pathological progression in neurodegenerative diseases. In this work, we present a generalised and extended formulation of the Boundary Shift Integral (gBSI) using probabilistic segmentations in order to estimate anatomical changes between 2 time points. This method adaptively estimates a non-binary XOR region-of-interest from probabilistic brain segmentations of the baseline and repeat scans, in order to better localise and capture the brain atrophy. We evaluate the proposed method by comparing the sample size requirements for a hypothetical clinical trial of Alzheimer’s disease to that needed for the current implementation of BSI as well as a fuzzy implementation of BSI. The gBSI method results in a modest, but reduced sample size, providing increased sensitivity to disease changes through the use of the probabilistic XOR region.
    Neurobiology of Aging 08/2014; 36(Suppl 1). DOI:10.1016/j.neurobiolaging.2014.04.035 · 5.01 Impact Factor
  • Source
    • "We selected measures for whole brain, ventricular, and hippocampal volume. For measurement of whole brain and ventricular volume boundary shift integral (BSI) was used [14] [15]. Whole brain and ventricles were first semiautomatically delineated from T1-weighted MRI. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background We investigated the pattern of disease progression in the asymptomatic, mild cognitive impairment (MCI), and dementia stage of Alzheimer's disease (AD). Methods We selected 284 subjects with AD pathology, defined as abnormal levels of amyloid beta 1–42 (Aβ1–42) in cerebrospinal fluid (CSF). Disease outcome measures included six biomarkers and five cognitive markers. We compared differences in baseline measures and decline over 4 years between the AD stages and tested whether these changes differed from subjects, without AD pathology (N = 132). Results CSF Aβ1–42 reached the maximum abnormality level in the asymptomatic stage and tau in the MCI stage. The imaging and cognitive markers started to decline in the asymptomatic stage, and decline accelerated with advancing clinical stage. Conclusion This study provides further evidence for a temporal evolution of AD biomarkers. Our findings may be helpful to determine stage specific outcome measures for clinical trials.
    Alzheimer's and Dementia 08/2014; 11(5). DOI:10.1016/j.jalz.2014.05.1754 · 12.41 Impact Factor
Show more